葵花药业10月22日获融资买入614.86万元，融资余额1.55亿元

Core Insights - On October 22, Kewang Pharmaceutical's stock rose by 1.17%, with a trading volume of 798.94 million yuan [1] - As of September 30, the number of shareholders decreased by 2.06% to 52,400, while the average circulating shares per person increased by 2.10% to 11,145 shares [2] Financing and Margin Trading - On October 22, Kewang Pharmaceutical had a financing buy amount of 6.15 million yuan and a financing repayment of 13.38 million yuan, resulting in a net financing buy of -7.24 million yuan [1] - The total margin trading balance as of October 22 was 157 million yuan, with the financing balance at 155 million yuan, accounting for 1.70% of the circulating market value, which is below the 10th percentile level over the past year [1] - The company had a short selling repayment of 800 shares and a short selling amount of 900 shares on October 22, with a short selling balance of 127.93 million yuan, also below the 10th percentile level over the past year [1] Financial Performance - For the first half of 2025, Kewang Pharmaceutical reported a revenue of 1.31 billion yuan, a year-on-year decrease of 48.17%, and a net profit attributable to shareholders of 81.31 million yuan, down 83.28% year-on-year [2] - Cumulatively, the company has distributed 4.045 billion yuan in dividends since its A-share listing, with 1.752 billion yuan distributed over the past three years [3] Shareholder Structure - As of June 30, 2025, the top ten circulating shareholders included E Fund CSI Dividend ETF, which held 3.1612 million shares, a decrease of 436,800 shares from the previous period [3] - Hong Kong Central Clearing Limited entered as a new shareholder, holding 2.9699 million shares, while Southern CSI 1000 ETF also entered as a new shareholder with 2.6960 million shares [3]